• Cardiovascular Disease
    • Director of Cardiometabolic Disorders, Mount Sinai Heart at Mount sinai

    Robert S. Rosenson, MD, is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Director of Cardiometabolic Disorders at Mount Sinai Heart, New York, New York. He received his medical degree at Tulane University, New Orleans, Louisiana, and went on to complete his residency in internal medicine at Brigham and Women’s Hospital, Boston, Massachusetts, followed by a fellowship in cardiovascular medicine at The University of Chicago, Chicago, Illinois.

    Dr Rosenson is a Fellow of the American College of Cardiology (FACC),  American College of Physicians (FACP), College of Chest Physicians (FCCP), Fellow of the American Heart Association (FAHA) Council on Arteriosclerosis, Thrombosis, and Vascular Biology, and the AHA Council on Epidemiology and Prevention, European Society of Cardiology (FESC) and National Lipid Association (FNLA).  Dr Rosenson was Global PI of the PLASMA I, PLASMA II, FRANCIS and BANTING trials. He is the recipient of numerous awards and honors, including the Ground-Breaking Doctors Award from Chicago magazine, and was named New York Top Doc from 2015 to 2021 and USA Top Doctor in 2019. Dr Rosenson was named recipient of the Simon Dack Award for outstanding scholarship by the Journal of the American College of Cardiology in 2015, 2016, 2017,  2019 and 2020. The International Academy of Cardiology honored him with the Jan J. Kellerman Memorial Award in 2016 for distinguished contributions in the field of cardiovascular disease prevention. In 2017, UpToDate recognized him for 20 years of Outstanding Contributions as Editor. In 2019, he was awarded the Clinician Educator Award from the National Lipid Association. He was selected by the Univesity of Toronto for the “Great Minds and Great Medicine: Isadore Rosenfeld Visiting Lectureship

    He is former co-Editor in Chief for Cardiovascular Drugs and Therapy, Section Editor on Metabolic Disorders for the Journal of the American College of Cardiology, and Section Editor on Lipid Disorders for UptoDate.

  • Dr. Seth J. Baum, a graduate of Columbia College and Columbia College of Physicians and Surgeons, is a fellow of the American College of Cardiology, the American Heart Association, the National Lipid Association, and the American Society for Preventive Cardiology. He is a past President of the American Society for Preventive Cardiology. Clinical Affiliate Professor of Cardiolgy at FAU Medical School, he has published over 100 peer reviewed papers and abstracts as well as two books. In 2013 he was awarded Cleveland Heart Laboratory’s “Heart Award” for lifelong dedication to Preventive Medicine. In 2019 Dr. Baum received Mended Hearts’ Dwight Emary Harken Award, which is presented every two years. Dr. Baum is the Founder of Excel Medical Clinical Trials and has served as Principal Investigator in over 75 studies covering a broad band of disease states, including atherosclerotic cardiovascular disease and lipid/lipoprotein disorders.

    Dr. Baum maintains a small consultative practice and continues to direct the lipoprotein apheresis program in southeast Florida.

    • Cardiovascular Disease

    Robert Pordy, MD, FACP - Senior pharmaceutical physician executive with over 30 years’ experience and in-depth knowledge of multiple therapeutic areas and all phases of drug development. Successful negotiations with regulatory agencies globally, including launching of several new cardiovascular medications. Currently Vice President, Clinical Sciences - Cardiovascular and Metabolism at Regeneron Pharmaceuticals Inc. Involved in all clinical aspects of evinacumab, from first-in-human through BLA filing.

Powered by Medstro